These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 12654699)

  • 21. In vitro susceptibility of El Tor and classical Vibrio cholerae strains to trimethoprim and sulfamethoxazole.
    Northrup RS; Doyle MA; Feeley JC
    Antimicrob Agents Chemother; 1972 Apr; 1(4):310-4. PubMed ID: 4670695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of polymyxin E on Vibrio cholerae].
    Noworyta J
    Med Dosw Mikrobiol; 1978; 30(4):221-32. PubMed ID: 750785
    [No Abstract]   [Full Text] [Related]  

  • 23. [The antibacterial effect of niridazole on Vibrio cholerae strains].
    Füzi M
    Orv Hetil; 1983 Sep; 124(38):2293-5. PubMed ID: 6634168
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of iron and pH on the survival of Vibrio cholerae in water.
    Patel M; Isaäcson M; Gouws E
    Trans R Soc Trop Med Hyg; 1995; 89(2):175-7. PubMed ID: 7778142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibacterial effect of niridazole on Vibrio cholerae strains.
    Füzi M
    Ther Hung; 1986; 34(3):159-62. PubMed ID: 3441879
    [No Abstract]   [Full Text] [Related]  

  • 26. Susceptibility to rifaximin of Vibrio cholerae strains from different geographical areas.
    Scrascia M; Forcillo M; Maimone F; Pazzani C
    J Antimicrob Chemother; 2003 Aug; 52(2):303-5. PubMed ID: 12837732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Accuracy of Etest method to study Campylobacter spp. susceptibility to erythromycin, ciprofloxacin and tetracycline].
    Sanz-Rodríguez N; Pérez-Pomata MT; Stelmakh O; Pérez-Boto D; Gómez-Garcés JL
    Rev Esp Quimioter; 2013 Jun; 26(2):116-8. PubMed ID: 23817649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional analysis of Vibrio vulnificus RND efflux pumps homologous to Vibrio cholerae VexAB and VexCD, and to Escherichia coli AcrAB.
    Lee S; Yeom JH; Seo S; Lee M; Kim S; Bae J; Lee K; Hwang J
    J Microbiol; 2015 Apr; 53(4):256-61. PubMed ID: 25740377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative trial of erythromycin and sulphatrimethoprim in the treatment of tetracycline-resistant Vibrio cholerae O1.
    Burans JP; Podgore J; Mansour MM; Farah AH; Abbas S; Abu-Elyazeed R; Woody JN
    Trans R Soc Trop Med Hyg; 1989; 83(6):836-8. PubMed ID: 2617655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibiotic sensitivity of Vibrio cholerae other than O serotype 1 (so-called NAG vibrios).
    Sanyal SC; Mukherjee S; Sil J
    Indian J Med Res; 1974 Apr; 62(4):491-6. PubMed ID: 4435860
    [No Abstract]   [Full Text] [Related]  

  • 31. Emergence of nalidixic acid resistant Vibrio cholerae O-1 in Karachi.
    Mahmood A
    J Pak Med Assoc; 1999 Nov; 49(11):286. PubMed ID: 10647244
    [No Abstract]   [Full Text] [Related]  

  • 32. Global surveillance of antibiotic sensitivity of Vibrio cholerae.
    O'Grady F; Lewis MJ; Pearson NJ
    Bull World Health Organ; 1976; 54(2):181-5. PubMed ID: 1088100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucose sensitizes the stationary and persistent population of Vibrio cholerae to ciprofloxacin.
    Paranjape SS; Shashidhar R
    Arch Microbiol; 2020 Mar; 202(2):343-349. PubMed ID: 31664493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibiotic resistance pattern of Vibrio cholerae and Shigella causing diarrhoea outbreaks in the eastern Africa region: 1994-1996.
    Materu SF; Lema OE; Mukunza HM; Adhiambo CG; Carter JY
    East Afr Med J; 1997 Mar; 74(3):193-7. PubMed ID: 9185422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changing characteristics of Vibrio cholerae: emergence of multidrug resistance and non-O1, non-O139 serogroups.
    Chandrasekhar MR; Krishna BV; Patil AB
    Southeast Asian J Trop Med Public Health; 2008 Nov; 39(6):1092-7. PubMed ID: 19062701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitek system antimicrobial susceptibility testing of O1, O139, and non-O1 Vibrio cholerae.
    Sciortino CV; Johnson JA; Hamad A
    J Clin Microbiol; 1996 Apr; 34(4):897-900. PubMed ID: 8815104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The chemosensitivity of strains of Vibrio cholerae group O1 isolated in Romania between 1977-1995].
    Israil A; Năcescu N; Cedru C; Balotescu C
    Bacteriol Virusol Parazitol Epidemiol; 1997; 42(4):213-20. PubMed ID: 9586330
    [No Abstract]   [Full Text] [Related]  

  • 38. [Comparative in vitro study of antibiotic resistance increase in classical cholera and E1 Tor vibrios].
    Ganin VS; Khundanov LE; Navashin SM
    Antibiotiki; 1971 Sep; 16(9):831-4. PubMed ID: 4333292
    [No Abstract]   [Full Text] [Related]  

  • 39. Ofloxacin-resistant Vibrio cholerae O139 in Hong Kong.
    Kam KM; Luey KY; Cheung TL; Ho KY; Mak KH; Saw PT
    Emerg Infect Dis; 1999; 5(4):595-7. PubMed ID: 10458975
    [No Abstract]   [Full Text] [Related]  

  • 40. Plasmid profiles and antimicrobial susceptibility patterns of Vibrio cholerae O1 strain isolated during a recent outbreak in Nigeria.
    Olukoya DK; Ogunjimi AA; Abaelu AM
    J Diarrhoeal Dis Res; 1995 Jun; 13(2):118-21. PubMed ID: 7594312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.